GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avacta Group PLC (OTCPK:AVCTF) » Definitions » Total Assets

Avacta Group (Avacta Group) Total Assets : $92.65 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Avacta Group Total Assets?

Avacta Group's Total Assets for the quarter that ended in Dec. 2023 was $92.65 Mil.

Warning Sign:

If a company builds assets at 28.4% a year, faster than its revenue growth rate of 10.2% over the past 5 years, it means that the company may be getting less efficient.

During the past 12 months, Avacta Group's average Total Assets Growth Rate was 11.20% per year. During the past 3 years, the average Total Assets Growth Rate was 42.50% per year. During the past 5 years, the average Total Assets Growth Rate was 28.40% per year. During the past 10 years, the average Total Assets Growth Rate was 11.60% per year.

During the past 13 years, Avacta Group's highest 3-Year average Total Assets Growth Rate was 1914.60%. The lowest was -82.30%. And the median was 20.40%.

Total Assets is connected with ROA %. Avacta Group's annualized ROA % for the quarter that ended in Dec. 2023 was -33.39%. Total Assets is also linked to Revenue through Asset Turnover. Avacta Group's Asset Turnover for the quarter that ended in Dec. 2023 was 0.14.


Avacta Group Total Assets Historical Data

The historical data trend for Avacta Group's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avacta Group Total Assets Chart

Avacta Group Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Dec20 Dec21 Dec22 Dec23
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.86 90.68 62.50 112.85 92.65

Avacta Group Semi-Annual Data
Jul13 Jan14 Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.50 55.99 112.85 110.79 92.65

Avacta Group Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Avacta Group's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=27.601+65.046
=92.65

Avacta Group's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (Q: Dec. 2023 )+Total Liabilities (Q: Dec. 2023 )
=27.601+65.046
=92.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avacta Group  (OTCPK:AVCTF) Total Assets Explanation

Total Assets is connected with ROA %.

Avacta Group's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=-33.962/( (110.793+92.647)/ 2 )
=-33.962/101.72
=-33.39 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Avacta Group's Asset Turnover for the quarter that ended in Dec. 2023 is

Asset Turnover
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Jun. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=14.377/( (110.793+92.647)/ 2 )
=14.377/101.72
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Avacta Group Total Assets Related Terms

Thank you for viewing the detailed overview of Avacta Group's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Avacta Group (Avacta Group) Business Description

Traded in Other Exchanges
Address
Unit 20, Ash Way, Thorp Arch Estate, West Yorkshire, Wetherby, GBR, LS23 7FA
Avacta Group PLC is a United Kingdom-based biotechnology company. The company offers its products through three segments that are Diagnostics, Therapeutics, and Animal Health. The company is developing novel cancer immunotherapies combining its two proprietary platforms Affimer biotherapeutics and precision tumor-targeted chemotherapy. The company operates in the United Kingdom, France, South Korea, Rest of Europe, Asia, and North America.

Avacta Group (Avacta Group) Headlines

From GuruFocus

Avacta Appoints COVID-19 Rapid Antigen Test Manufacturing Partner

By Business Wire Business Wire 08-06-2020

Avacta and LG Chem Life Sciences Expand Partnership

By Business Wire Business Wire 08-18-2020

Avacta Announces License Agreement With POINT Biopharma Inc.

By Business Wire Business Wire 01-07-2021

Avacta Selects Second pre|CISION� Pro-drug Candidate for Development

By Business Wire Business Wire 01-18-2022

Avacta's Diagnostic Division Achieves ISO 13485 Certification

By Business Wire Business Wire 07-14-2021

Avacta Launches SARS-CoV-2 BAMS Research Test

By Business Wire Business Wire 09-30-2020